There is no specific target weight to stop Mounjaro (tirzepatide)
The decision to discontinue Mounjaro should be based on treatment response assessment at 3 months, not achievement of a specific target weight. Current guidelines and evidence support ongoing, long-term treatment for obesity management rather than stopping at a predetermined weight goal.
Treatment Response Assessment
Evaluate efficacy at 3 months after reaching maximum tolerated dose:
- Continue treatment if ≥5% weight loss achieved 1, 2, 3
- Consider discontinuation if <5% weight loss after 3 months on maintenance dose 1, 3
This 5% threshold applies across anti-obesity medications and represents the standard for determining treatment effectiveness. The most recent 2025 ADA guidelines 3 emphasize that early responders (those achieving >5% weight loss at 3 months) have improved long-term outcomes and should continue medication long-term.
Obesity as a Chronic Disease Requiring Long-Term Management
Obesity requires ongoing treatment, similar to other chronic diseases like hypertension or diabetes 4, 3. The 2016 AACE/ACE guidelines 4 explicitly state that obesity should be approached as a chronic medical illness requiring continuous management, not a condition to be "cured" and then treatment stopped.
Critical evidence on weight regain: Sudden discontinuation of tirzepatide results in regain of one-half to two-thirds of the weight loss within 1 year 3. The SURMOUNT-MAINTAIN trial 5 demonstrated that participants who switched from tirzepatide to placebo regained significant weight, with 67% requiring rescue therapy due to regaining ≥50% of lost weight, compared to only 8% who continued tirzepatide at maximum tolerated dose.
When to Consider Stopping or Dose Reduction
Rather than stopping at a target weight, consider these scenarios:
Acceptable reasons to modify or discontinue:
- Achievement of treatment goals with patient preference to stop - but counsel on high likelihood of weight regain 3, 5
- Intolerable side effects despite dose adjustments 3
- Development of contraindications (personal/family history of medullary thyroid cancer, MEN2, pregnancy) 2
- Severe adverse events (pancreatitis, severe gallbladder disease) 6
Dose reduction strategy (not complete discontinuation):
The SURMOUNT-MAINTAIN trial 5 showed that reducing from maximum tolerated dose (10-15 mg) to 5 mg tirzepatide maintained -16.6% weight loss at 112 weeks, compared to -9.9% with placebo. This provides evidence that dose reduction to 5 mg may be a viable alternative to complete discontinuation for patients who have achieved substantial weight loss and prefer lower dosing.
Common Pitfalls to Avoid
Do not stop tirzepatide simply because:
- Patient reached a "normal" BMI <25 kg/m² - obesity is a chronic disease requiring ongoing management 4, 3
- Patient achieved their subjective weight goal - without ongoing treatment, weight regain is highly likely 3, 5
- Patient has been on treatment for an arbitrary duration - there is no maximum treatment duration; trials demonstrate safety and efficacy beyond 100 weeks 5, 7
Warning about BMI <18.5 kg/m²: Only 0.38% of tirzepatide-treated participants reached BMI <18.5 kg/m² in clinical trials 8. If this occurs, treatment modification is warranted, but this represents an extremely rare scenario.
Practical Management Algorithm
At 3 months on maximum tolerated dose:
- ≥5% weight loss achieved → Continue long-term treatment 1, 3
- <5% weight loss → Evaluate glycemic response, treatment tolerance, and other benefits; consider intensifying with additional approaches or discontinuing 3
For patients achieving substantial weight loss who desire treatment modification:
- First option: Continue at lowest effective dose (may reduce from 10-15 mg to 5 mg) 5
- Second option: Close monitoring with plan to reinitiate if weight regain occurs 3
- Avoid: Abrupt discontinuation without monitoring plan
Ongoing monitoring: Assess at least quarterly after initial 3-month evaluation period 3. Monitor for weight regain, and avoid treatment inertia by reevaluating and intensifying treatment if goals are not maintained.
The evidence strongly supports that tirzepatide is a long-term treatment for the chronic disease of obesity, not a short-term intervention to reach a specific weight target 4, 3, 5.